Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 8;12:1173–1181. doi: 10.2147/DDDT.S109489

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Sahota and Robinson. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Effect of reslizumab versus placebo on exacerbation frequency and FEV₁.

Notes: (A) Kaplan–Meier plot showing frequency versus time for remaining exacerbation free in patients treated with reslizumab or placebo for one of the two Phase III studies. (B) Change in FEV₁ over time for patients treated with reslizumab or placebo in one of the two Phase III studies. *p<0.05. ^#p<0.01. Reprinted from Lancet Respir Med, 2015;3:355–366. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Copyright (2015), with permission from Elsevier.27

Abbreviations: CAE, clinical asthma exacerbations; FEV₁, forced expiratory volume in the first second of expiration; HR, hazard ratio; LS, least squares.